Systematic Review: Outcomes and Adverse Events From Randomised Trials in Crohn's Disease



Catt, Heather ORCID: 0000-0001-9515-7497, Hughes, Dyfrig ORCID: 0000-0001-8247-7459, Kirkham, Jamie ORCID: 0000-0003-2579-9325 and Bodger, Keith ORCID: 0000-0002-1825-3239
(2019) Systematic Review: Outcomes and Adverse Events From Randomised Trials in Crohn's Disease. Alimentary Pharmacology and Therapeutics, 49 (8). 978 - 996.

This is the latest version of this item.

[img] Text
Systematic review APT Final for Liverpool depository.docx - Accepted Version

Download (554kB)
[img] Text
Catt_et_al-2019-Alimentary_Pharmacology_&_Therapeutics (1).pdf - OA Published Version

Download (964kB)

Abstract

Background The suitability of disease activity indices has been challenged, with growing interest in objective measures of inflammation. Aim To undertake a systematic review of efficacy and safety outcomes in placebo‐controlled randomised controlled trials (RCTs) of patients with Crohn's disease. Methods MEDLINE, EMBASE, CINAHL and Cochrane Library were searched until November 2015, for RCTs of adult Crohn's disease patients treated with medical or surgical therapies. Data on efficacy and safety outcomes, end‐point definitions, and measurement instruments were extracted and stratified by publication date (pre‐2009 and 2009 onwards). Results One hundred and eighty‐one RCTs (110 induction and 71 maintenance) were identified, including 23 850 patients. About 92.3% reported clinical efficacy endpoints. The Crohn's Disease Activity Index (CDAI) dominated, defining clinical response or remission in 63.5% of trials (35 definitions of response or remission). CDAI < 150 was the commonest endpoint, but reporting reduced between periods (46.4%‐41.1%), whilst use of CDAI100 increased (16.8%‐30.4%). Fistula studies most commonly reported fistula closure (9, 90.0%). Reporting of biomarker, endoscopy and histology endpoints increased overall (33.3%‐40.6%, 14.4%‐30.4% and 3.2%‐12.5%, respectively), but were heterogeneous and rarely reported in fistula trials. Patient‐reported outcome measures were reported in 41.4% of trials and safety endpoints in 35.4%. Many of the common adverse events relate to disease exacerbation or treatment failure. Conclusions Trial endpoints vary across studies, over time and are distinct in fistula studies. Despite growth in reporting of objective measures of inflammation and in patient‐reported outcome measures, there is a lack of standardisation. This confirms the need for a core outcome set for comparative effectiveness research in Crohn's disease.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 04 Mar 2019 16:16
Last Modified: 09 Nov 2021 09:49
DOI: 10.1111/apt.15174
Open Access URL: https://doi.org/10.1111/apt.15174
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3033744

Available Versions of this Item